1. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis
- Author
-
Lilla Lörincz, B. Zörner, Linard Filli, Michael Linnebank, Michael Weller, Katja Reuter, David Weller, Tabea Sutter, University of Zurich, and Filli, L
- Subjects
medicine.medical_specialty ,Multiple Sclerosis ,610 Medicine & health ,Walking ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Potassium Channel Blockers ,Humans ,Medicine ,In patient ,030212 general & internal medicine ,4-Aminopyridine ,Ground reaction force ,business.industry ,Multiple sclerosis ,medicine.disease ,Gait ,Crossover study ,10040 Clinic for Neurology ,Clinical trial ,Preferred walking speed ,Kinetics ,2728 Neurology (clinical) ,Treatment Outcome ,Neurology ,2808 Neurology ,Neurology (clinical) ,business ,human activities ,030217 neurology & neurosurgery - Abstract
Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-release fampridine (PR-fampridine) improves walking ability in some PwMS. Associated fampridine-induced changes in the walking pattern are still poorly understood but may provide a better understanding of the mechanisms underlying the beneficial drug effects. 61 PwMS were treated with PR-fampridine in a randomized, monocentric, double-blind and placebo-controlled clinical trial with crossover design (FAMPKIN). Drug-induced improvements in walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute Walk Test; 6MWT) were quantified. In this sub-study of the FAMPKIN trial, fampridine-induced changes in kinetic gait patterns were analyzed by pressure-based foot print analysis during treadmill walking. Vertical ground reaction forces were analyzed during different gait phases. Kinetic data of 44 PwMS was eligible for analysis. During double-blind treatment with PR-fampridine, patients performed significantly better in the T25FW and 6MWT than during placebo treatment (p < 0.0001 for both). At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo. However, we found relevant changes of walking kinetics regarding forces during loading, single limb and pre-swing phase in a patient sub-group (n = 8). Interestingly, this sub-group demonstrated superior responsiveness to PR-fampridine in the clinical walking tests compared to those patients without any fampridine-induced changes in kinetics (n = 36). Our results demonstrate fampridine-induced changes in gait kinetics in a sub-group of PwMS. These gait pattern changes were accompanied by improved clinical walking performance under PR-fampridine. These results shed some light on the biomechanical changes in walking patterns underlying enhanced fampridine-induced gait performance.
- Published
- 2020
- Full Text
- View/download PDF